PDCD1 and cutaneous melanoma: Results from another cohort study using the DMTR data from 885 patients aged ≥ 65 years with resected stage III or IV cutaneous melanoma treated with adjuvant anti-PD-1 therapy in the period from 2018 until 2022, showed that older patients had similar recurrence-free survival (RFS) to the one observed in the same age group in previously conducted clinical trials [82].